Regeneron antibody development outlined in PNAS

Regeneron Pharmaceuticals, Inc. said Monday a paper detailing the success of it's VelociGene and VelocImmune in rapid identification validation of treatment candidates for Middle East respiratory syndrome (MERS) has been published in the Proceeedings of the National Academy of Sciences (PNAS).

Specifically the technology was used in order to determine a possible effective treatment option for the MERS coronavirus. The company is currently in a collaboration with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services in researching methods against MERS and the Ebola viruses.
"Regeneron is committed to being part of the solution in responding to emerging epidemics, and we hope to collaborate with governments and other organizations in an effort to make our antibodies for MERS and Ebola available," Regeneron Executive Vice President of Research and Development Neil Stahl said. "Fully human antibodies hold incredible promise for treating infectious disease; however, earlier generation technologies were not optimal for rapid enough development so as to address emerging outbreaks. Our Veloci-technologies identify and produce validated fully human antibodies, already in manufacturing-ready cell lines, within months as compared to years using other methods."

This technology and the use of antibodies could have potential in treating these and other emerging diseases. Currently no approved treatments exist for MERS or the Ebola virus.